Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Liabilities and Shareholders Equity (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Liabilities and Shareholders Equity for 4 consecutive years, with $507.8 million as the latest value for Q4 2025.

  • Quarterly Liabilities and Shareholders Equity fell 12.86% to $507.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 billion through Dec 2025, up 8.6% year-over-year, with the annual reading at $507.8 million for FY2025, 12.86% down from the prior year.
  • Liabilities and Shareholders Equity for Q4 2025 was $507.8 million at Day One Biopharmaceuticals, down from $513.8 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $600.8 million in Q3 2024, with the low at $267.8 million in Q1 2022.
  • Average Liabilities and Shareholders Equity over 4 years is $434.6 million, with a median of $409.1 million recorded in 2022.
  • Peak annual rise in Liabilities and Shareholders Equity hit 63.59% in 2025, while the deepest fall reached 14.49% in 2025.
  • Over 4 years, Liabilities and Shareholders Equity stood at $349.1 million in 2022, then increased by 7.73% to $376.0 million in 2023, then surged by 54.98% to $582.8 million in 2024, then decreased by 12.86% to $507.8 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $507.8 million, $513.8 million, and $519.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.